GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SIGA Technologies Inc (NAS:SIGA) » Definitions » 3-Year RORE %

SIGA Technologies (SIGA Technologies) 3-Year RORE % : 2.31% (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is SIGA Technologies 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. SIGA Technologies's 3-Year RORE % for the quarter that ended in Dec. 2023 was 2.31%.

The industry rank for SIGA Technologies's 3-Year RORE % or its related term are showing as below:

SIGA's 3-Year RORE % is ranked better than
50.75% of 1003 companies
in the Drug Manufacturers industry
Industry Median: 1.82 vs SIGA: 2.31

SIGA Technologies 3-Year RORE % Historical Data

The historical data trend for SIGA Technologies's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SIGA Technologies 3-Year RORE % Chart

SIGA Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.68 -77.43 72.55 -13.06 2.31

SIGA Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.06 -16.61 -8.94 -17.91 2.31

Competitive Comparison of SIGA Technologies's 3-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, SIGA Technologies's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SIGA Technologies's 3-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SIGA Technologies's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where SIGA Technologies's 3-Year RORE % falls into.



SIGA Technologies 3-Year RORE % Calculation

SIGA Technologies's 3-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.95-0.897 )/( 2.297-0 )
=0.053/2.297
=2.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 3-year before.


SIGA Technologies  (NAS:SIGA) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


SIGA Technologies 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of SIGA Technologies's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


SIGA Technologies (SIGA Technologies) Business Description

Traded in Other Exchanges
N/A
Address
31 East 62nd Street, New York, NY, USA, 10065
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus.
Executives
Evan A. Knisely director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Jay Varma director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Ford Harold Eugene Jr. director 4921 WILLIAM ARNOLD ROAD, MEMPHIS TN 38117
James Antal director 30952 STEEPLECHASE DRIVE, SAN JUAN CAPISTRANO CA 92675
Holly L. Phillips director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Gary J. Nabel director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Julian Nemirovsky director 35 EAST 62ND STREET, NEW YORK NY 10065
Edward P. Taibi director 35 EAST 62ND STREET, NEW YORK NY 10065
Jaymie A Durnan director C/O SIGA TECHNOLOGIES, INC.,, 31 EAST 62ND STREET, NEW YORK NY 10065
Gomez Phillip Louis Iii officer: Chief Executive Officer 7220 VAN NESS COURT, MCLEAN VA 22101
Daniel J Luckshire officer: Executive VP & CFO C/O SIGA TECHNOLOGIES, INC., 35 EAST 62ND STREET, NEW YORK NY 10065
Paul G Savas director 35 EAST 62ND STREET, NEW YORK NY 10021
Julie Kane director 77 BEALE ST, P.O. BOX 770000, SAN FRANCISCO CA 94177
Dennis E Hruby officer: Chief Scientific Officer SIGA TECHNOLOGIES, INC., 420 LEXINGTON AVENUE, SUITE 601, NEW YORK NY 10170
Michael J Bayer director 1100 N GLEBE ROAD, ARLINGTON VA 22201

SIGA Technologies (SIGA Technologies) Headlines

From GuruFocus

SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX � (tecovirimat) for Treatment of Monkeypox

By deactivated_deactivated_Ds*** deactivated_deactivated_Ds*** 10-12-2022